14335-29-6

Basic information

• Product Name: Glycyl diphenylborinate, 95%
• Synonyms: Glycyl diphenylborinate, 95%
• CAS NO: 14335-29-6
• Molecular Formula: C₁₄H₁₄BNO₂
• Molecular Weight: 239.07746
• Mol File: 14335-29-6.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Glycyl diphenylborinate, 95%(CAS DataBase Reference)
• NIST Chemistry Reference: Glycyl diphenylborinate, 95%(14335-29-6)
• EPA Substance Registry System: Glycyl diphenylborinate, 95%(14335-29-6)

Safety Data

• Hazardous Substances Data: 14335-29-6(Hazardous Substances Data)

Upstream product

• 2622-89-1 diphenylborinic acid 
• 6000-44-8 sodium glycinate 
• 56-40-6 glycine 
• 524-95-8 2-Aminoethoxydiphenylborane 
• 4426-21-5 oxybis(diphenylborane) 

Relevant articles and documents

In vitro apoptotic activity of 2,2-diphenyl-1,3,2-oxazaborolidin-5-ones in L5178Y cells

Compounds containing B-N bonds have shown interesting biological activity. One class of such molecules is the 2,2-diphenyl-1,3,2-oxazaborolidin-5-ones (3a-j), which contain a B-N bond, have an α-amino acid moiety in the heterocycle, and have an exocyclic

2-Aminoethoxydiphenyl borate as a prototype drug for a group of structurally related calcium channel blockers in human platelets

We have synthesized a series of 2-aminoethoxydiphenyl borate (2-APB, 2,2-diphenyl-1,3,2-oxazaborolidine) analogs and tested their ability to inhibit thrombin-induced Ca2+ influx in human platelets. The analogs were either synthesized by adding various substituents to the oxazaborolidine ring (methyl, dimethyl, tert-butyl, phenyl, methyl phenyl, and pyridyl) or increasing the size of the oxazaborolidine ring to seven- and nine-membered rings. NMR analysis of the boron-containing analogs suggests that each of them exist as a ring structure through the formation of an N→B coordinate bond (except for the hexyl analog). The possibility that these boron-containing compounds formed dimers was also considered. All compounds dose-dependently inhibited thrombin-induced Ca2+ influx in human platelets, with the 2,2-diphenyl-1,3,2-oxazaborolidine-5-one derivative having the weakest activity at 100 μM, whereas the (S)-4-benzyl and (R)-4-benzyl derivatives of 2-APB were approximately 10 times more potent than the parent 2-APB. Two nonboron analogs (3-methyl and 3-tert-butyl 2,2-diphenyl-1,3-oxazolidine) were synthesized; they had approximately the same activity as 2-APB, and this implies that the presence of boron was not necessary for inhibitory activity. All of the compounds tested were also able to inhibit thrombininduced calcium release. We concluded that extensive modifications of the oxazaborolidine ring in 2-APB can be made, and Ca2+-blocking activity was maintained. Copyright